Every Child by Two proclaims that vaccines save money! Lots and lots of money!
Childhood Vaccines Save Lives and Money
- Routine childhood immunization
- 33,000 deaths prevented
- $43 billion saved
But then, on the side of their web-page, is a link to a graphic illustration of the rising costs of childhood vaccination.
Looks like they want it both ways: “vaccines save billions” by reducing health care costs, preventing hospitalizations and doctor visits; BUT “the newer vaccines are more expensive and we need to put a lot more tax dollars into vaccination programs.”
If the numbers with respect to “dollars saved” were solid and existed across the entire vaccine program, the argument would be a good one. Upon further scrutiny, it looks like they are pulling a bait and switch. They put forward some old numbers based on the less expensive vaccines combined with some inflated statistics for predicted epidemics (see the “33,000 deaths prevented” link above for our detailed analysis of these numbers), then slide right past the huge increase in the number and cost of vaccines in the current U.S. schedule.
On top of this, some of the newer vaccines are aimed at illnesses which are of low incidence or fairly mild in most children. For example, Hepatitis B is very severe, but it isn’t common among infants born in the U.S. On the other side, chickenpox is usually a minor illness, although common. The chickenpox vaccine cost benefit justification actually depended on a monetary estimate of the cost of parental time lost from work. Some convoluted bookkeeping methods would be needed to demonstrate that universal vaccination with ALL of the vaccines on the current schedule results in overall health care savings. There is certainly no sign of these savings in the escalating cost of health insurance in the U.S. Read more
In November of 2008, a report was published about a halted vaccine trial in India. Here is an excerpt which can be found on Livemint :
New Delhi: Patient trials of an advanced pneumonia vaccine by the domestic unit of US drug giant Wyeth Inc. have been suspended by India’s drug quality regulator after the death of an infant on whom the vaccine was tested in a trial in Bangalore.
The child had a pre-existing cardiac disorder. Indian drug rules prohibit testing on human subjects with such conditions without the prior approval of the drugs controller general of India (DCGI), the drugs quality regulator.
Indian authorities said that the trial was stopped because:
“The baby was suffering from a cardiac abnormality and should not have been included in the trial at all. It seems that the ‘inclusion-exclusion’ criteria protocol has not been adhered to by the investigator,” said Surinder Singh, drugs controller general. “We have suspended all further trials across the country.”
Filed under: News, Parents' Pages, Vaccine Science, Vaccine/Disease Analysis, WHO Watch
It’s that time of year again! Having spent last summer consulting the avian set on what’s hot in influenza, the pharmaceutical company has whipped up a fresh batch of flu vaccine, and now they need to move the merchandise! Fortunately, the CDC is happy to help with sales, by expanding the recommendation to ever more age groups. The Advisory Committee on Immunization Policy currently recommends the vaccine for all children aged 6 months to eighteen years. There is just one slight issue that might concern some parents. Peer-reviewed research in The Archives of Pediatric and Adolescent Medicine, Vol. 162 No. 10, October 2008,1 demonstrates that the vaccine is not effective under age 5!
An inherent assumption of expanded vaccination recommendations is that the vaccine is efficacious in preventing clinical influenza disease. Although studies have documented immune responses following 2 doses of inactivated influenza vaccine as well as vaccine efficacy for culture-confirmed disease in randomized clinical trials, surprisingly little information exists regarding influenza vaccine effectiveness (VE) among young children receiving vaccine in routine health care settings.
VIENNA, Aug 28 (Reuters) – Austrian biotech firm Intercell <ICEL.VI> said on Thursday its partner Merck & Co <MRK.N> has started a Phase II clinical trial to evaluate a vaccine candidate against Staphylococcus aureus infections.
Merck is responsible for clinical development, manufacturing and marketing of the vaccine. Intercell is eligible to receive milestone payments and royalties on future net sales
This is the second trial start following a separate Phase II trial launch in December 2007. Read more
Scene: A pediatrician’s office. Behind the desk is the doctor, a pleasant, middle-aged woman in a white coat. Seated in front of the desk are the expectant parents, prosperous, educated, self-confident, and, in the case of the woman, exceedingly pregnant.
Doctor: So, what questions did you have for me today?
Mother: We are concerned about the current vaccine schedule.* We know that babies should be protected from serious diseases, but the current schedule is getting…well, strange. (Pulls a scroll from her purse and starts unwinding it, reading off the schedule as she goes, and inserting comments) So, at birth, they want our baby to get a Hepatitis B vaccination. We both test negative and are not at risk for that disease.
Father: Does our baby really need that one?